首页> 外文期刊>Der Pharmacia Lettre >Chemotherapy-induced Neutropenia in cancer patients with solidtumors in India
【24h】

Chemotherapy-induced Neutropenia in cancer patients with solidtumors in India

机译:印度患有实体瘤的癌症患者的化疗引起的中性粒细胞减少

获取原文
           

摘要

The present study was aimed to evaluate the incidences of chemotherapy-induced neutropenia and febrile neutropenia in the patients with solid tumors in India. The patients with carcinomas of breast, lung, ovary, colon, head and neck, and liver were divided in two groups. Group 1 was for the patients who experienced grade 0-2 neutropenia and Group 2 was for the patients with grade 3-4 neutropenia. Different types of chemotherapeutic agents were administered to the patients according to the routine practice of the physicians. The study revealed that the incidences of grade 3-4 neutropenia were observed in the patients with the first time exposure of the chemotherapeutic agents as well as the age factor also played an important role in the occurrence of neutropenia and febrile neutropenia. The results of this observational study indicate that the proportion of grade 0-2 neutropenia does not significantly (P-value 0.05) differ from the hypotheses value (i.e. 50%). Thus, we concluded that the proportion of incidence of grade 3-4 neutropenia is less as compared to proportion of grade 0-2 neutropenia. The grade of neutropenia and impaired chemotherapy delivery remain serious problems in most solid tumor carcinomas. Hence, proper preventive rather than reactive measures should be taken by the physicians, considering co-factors which are responsible for the occurrence of neutropenia, to avoid severe long-term implications.
机译:本研究旨在评估印度实体瘤患者化疗引起的中性粒细胞减少和发热性中性粒细胞减少的发生率。乳腺癌,肺癌,卵巢癌,结肠癌,头颈癌和肝癌患者分为两组。第一组用于经历0-2级中性粒细胞减少症的患者,第二组用于经历3-4级中性粒细胞减少的患者。根据医师的常规做法,向患者施用不同类型的化学治疗剂。研究表明,在首次接触化学治疗药物的患者中观察到3-4级中性粒细胞减少症的发病率以及年龄因素在中性粒细胞减少症和发热性中性粒细胞减少症的发生中也起着重要作用。这项观察性研究的结果表明,0-2级中性粒细胞减少的比例与假设值(即50%)没有显着差异(P值> 0.05)。因此,我们得出结论,与0-2级中性粒细胞减少的比例相比,3-4级中性粒细胞减少的发生比例更低。在大多数实体瘤癌中,嗜中性白血球减少症的程度和化学疗法的传递仍是严重的问题。因此,医师应考虑引起中性粒细胞减少症的辅助因素,采取适当的预防而非反应措施,以避免严重的长期影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号